Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR1F | P30939 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151959 | 0.85 | SYK (0.34) | GDAKDM4EPOLBL3MBTL1NPC1 | |
| SCHEMBL3426594 | 0.79 | MMP12 (0.32) | KDM4ELMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4405832 | 0.77 | CYP1A2 (0.50) | CYP1A2ADORA3ADORA1LMNACYP2C9 | |
| SCHEMBL7522894 | 0.77 | KDM4E (0.33) | KDM4E | |
| SCHEMBL30677393 | 0.77 | KDM4E (0.36) | KDM4EL3MBTL1LMNA | |
| SCHEMBL5072697 | 0.77 | EGFR (0.36) | KDM4E | |
| SCHEMBL30850504 | 0.77 | EGFR (0.36) | KDM4E | |
| SCHEMBL5828206 | 0.77 | KDM4E (0.36) | KDM4EL3MBTL1LMNA | |
| SCHEMBL4511037 | 0.77 | QPCT (0.30) | — | |
| SCHEMBL7771667 | 0.76 | SLC2A1 (0.37) | GDAKDM4EHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107722009-B | Process for producing cyclopropane derivative | 阿拉塔纳医疗股份有限公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3020712-B1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | ARATANA THERAPEUTICS NV (BE) | 2018-07-04 | — | — | EP | disclosed |
| EP-3020712-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | Aratana Therapeutics NV (BE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2776414-B1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | ARATANA THERAPEUTICS NV (BE) | 2016-03-16 | — | — | EP | disclosed |
| US-9040699-B2 | Method for preparing cyclopropane derivatives | ARATANA THERAPEUTICS NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-20150051394-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | ARATANA THERAPEUTICS NV (BE) | 2015-02-19 | — | — | US | disclosed |
| EP-2776414-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | Aratana Therapeutics NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068042-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | OKAPI SCIENCES NV (BE) | 2013-05-16 | — | — | WO | disclosed |
| EP-1816135-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | Ajinomoto Co., Inc. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | AJINOMOTO CO. INC. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051394-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | HTR6, P2RY6, HTR1D | GDA 1270/4885HTR1A 6/4885HTR1D 3/4885 |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | PNP, NUDT1, ADAR | GDA 104/4885HTR1A 1663/4885HTR1D 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.